31 completed, 9 terminated, 4 withdrawn, 3 active not recruiting. 33 Phase 2, 8 Phase 1, 3 Not applicable, 3 Phase 3.
Follow Somatostatinoma: new trials by email Literature Review of Somatostatinoma trials Research Report on Somatostatinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Multicenter Trial of ESK981 in Patients With Select Solid Tumors ESK981 - Pancreatic Adenocarcinoma, Adenosquamous Carcinoma | Phase 2 | Active not recruiting | University of Michigan Rogel Cancer Center | 17 | 2024-04-19 | 2026-05-14 |
| Assessment of What Patients and Healthcare Providers Value Survey Administration - Gastric Adenocarcinoma, Pancreatic Adenocarcinoma | Completed | M.D. Anderson Cancer Center | 397 | 2020-06-11 | 2022-08-31 | |
| Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin Fluorouracil, Leucovorin, Liposomal Irinotecan - Locally Advanced Digestive System Neuroendocrine Carcinoma, Locally Advanced Pancreatic Neuroendocrine Carcinoma | Phase 2 | Terminated | Roswell Park Cancer Institute | 11 | 2019-06-17 | 2025-01-30 |
| Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Capecitabine, Temozolomide, Veliparib - Functional Pancreatic Neuroendocrine Tumor, Malignant Somatostatinoma | Phase 1 | Withdrawn | Vanderbilt-Ingram Cancer Center | 2017-12-01 | 2017-09-28 | |
| Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery Sapanisertib - Pancreatic Neuroendocrine Tumor G1, Pancreatic Neuroendocrine Tumor G2 | Phase 2 | Completed | National Cancer Institute (NCI) | 13 | 2017-04-28 | 2023-10-17 |
| Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Biospecimen Collection, Computed Tomography, Echocardiography Test - Acinar Cell Carcinoma, Adenoid Cystic Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 798 | 2017-01-30 | 2026-06-17 |
| Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors regorafenib, laboratory biomarker analysis - Gastrinoma, Glucagonoma | Phase 2 | Completed | University of Southern California | 3 | 2016-08-16 | 2021-12-15 |
| Culture and Characterization of Circulating Tumor Cells (CTC) in Melanoma and Other Cancers Blood Draw - Melanoma | Completed | Wolfram Samlowski | 150 | 2016-06-01 | 2017-07-26 | |
| Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas Capecitabine, Carboplatin, Cisplatin - Gastric Neuroendocrine Carcinoma, Intestinal Neuroendocrine Carcinoma | Phase 2 | Active not recruiting | ECOG-ACRIN Cancer Research Group | 67 | 2015-11-06 | 2026-11-02 |
| A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET) Palbociclib - Pancreatic Neuroendocrine Cancer | Phase 2 | Completed | Grupo Espanol de Tumores Neuroendocrinos | 21 | 2015-05-01 | 2018-01-23 |
| Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II Sunitinib, 177Lu-DOTA0-Tyr3-Octreotate - Pancreatic Neuroendocrine Carcinoma | Phase 2 | Completed | Gustave Roussy, Cancer Campus, Grand Paris | 84 | 2015-02-01 | 2025-04-20 |
| Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer Everolimus - Estrogen Receptor-positive Breast Cancer, Gastrinoma | Phase 2 | Terminated | Emory University | 2 | 2014-11-01 | 2017-02-03 |
| Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors dovitinib lactate, pharmacological study, laboratory biomarker analysis - Gastrinoma, Glucagonoma | Phase 2 | Withdrawn | Academic and Community Cancer Research United | 2014-10-01 | 2017-07-19 | |
| Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery Computed Tomography Perfusion Imaging, Laboratory Biomarker Analysis, Ziv-Aflibercept - Multiple Endocrine Neoplasia Type 1, Pancreatic Neuroendocrine Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 22 | 2014-06-18 | 2020-03-23 |
| Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery everolimus, placebo - Gastrinoma, Glucagonoma | Phase 2 | Terminated | ECOG-ACRIN Cancer Research Group | 2 | 2014-04-10 | 2023-06-29 |
| Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors temozolomide, capecitabine - Gastrinoma, Glucagonoma | Phase 2 | Completed | ECOG-ACRIN Cancer Research Group | 144 | 2013-08-08 | 2026-09-29 |
| Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT gallium Ga 68-edotreotide, positron emission tomography/computed tomography, indium In 111 pentetreotide - Adult Medulloblastoma, Childhood Medulloblastoma | Phase 2 | Completed | Sue O'Dorisio | 68 | 2013-04-01 | 2021-09-22 |
| Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors Capecitabine, Temozolomide, Bevacizumab - Gastrinoma, Glucagonoma | Phase 2 | Completed | Shaheen Shagufta | 20 | 2012-12-01 | 2024-02-06 |
| Potential Molecular Predictors of Response to Novel Therapies in Metastatic Pancreatic Neuroendocrine Tumors MRI - Pancreatic Neuroendocrine Cancer | Completed | Memorial Sloan Kettering Cancer Center | 25 | 2012-05-14 | 2019-06-25 | |
| Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients" Exercise Intervention, Health Telemonitoring, Quality-of-Life Assessment - Malignant Head and Neck Neoplasm, Malignant Neoplasm | Not applicable | Recruiting | M.D. Anderson Cancer Center | 590 | 2011-05-25 | 2026-07-15 |
Showing 20 of 51. Sign in to see all of them.
Glucagonoma (31) · Insulinoma (31) · Carcinoma, Islet Cell (27) · Gastrinoma (27) · Vipoma (18) · Adenoma, Islet Cell (16) · Neoplasms (13) · Carcinoma, Medullary (9) · Pancreatic Neoplasms (9) · Pheochromocytoma (9) · Carcinoma, Hepatocellular (7) · Carcinoma, Renal Cell (7) · Neuroendocrine Tumors (7) · Bile Duct Neoplasms (6)
Adenocarcinoma (51) · Carcinoma (51) · Digestive System Diseases (51) · Digestive System Neoplasms (51) · Endocrine Gland Neoplasms (51) · Endocrine System Diseases (51) · Neoplasms by Histologic Type (51) · Neoplasms by Site (51) · Neoplasms, Germ Cell and Embryonal (51) · Neoplasms, Glandular and Epithelial (51) · Neuroectodermal Tumors (51) · Pancreatic Diseases (50) · Carcinoma, Neuroendocrine (49) · Neuroendocrine Tumors (44) · Pancreatic Neoplasms (42)
Capecitabine (6) · Temozolomide (5) · Everolimus (4) · Leucovorin (4) · Octreotide (4) · Bevacizumab (3) · Fluorouracil (3) · Biological Therapy (2) · Bortezomib (2) · Cisplatin (2) · Magnetic Resonance Spectroscopy (2) · Oxaliplatin (2) · Sunitinib (2) · Trastuzumab (2) · pentetreotide (2)
National Cancer Institute (NCI) (12) · ECOG-ACRIN Cancer Research Group (3) · Memorial Sloan Kettering Cancer Center (3) · Eastern Cooperative Oncology Group (2) · M.D. Anderson Cancer Center (2) · Mayo Clinic (2) · Vanderbilt-Ingram Cancer Center (2) · Yale University (2) · Academic and Community Cancer Research United (1) · Burzynski Research Institute (1) · Cambridge University Hospitals NHS Foundation Trust (1) · Columbia University (1) · Delcath Systems Inc. (1) · Emory University (1) · Federation Francophone de Cancerologie Digestive (1)
United States (42) · Spain (3) · United Kingdom (3) · Canada (2) · France (2) · Germany (2) · Argentina (1) · Australia (1) · Belgium (1) · Brazil (1) · Colombia (1) · Denmark (1) · Greece (1) · Guam (1) · Hong Kong (1)
James Yao (2) · Leonard B. Saltz, MD (2) · Mary Mulcahy, MD (2) · Timothy Hobday (2) · Anthony W. Tolcher, MD (1) · Arkadiusz Dudek, MD (1) · Daniel Halperin (1) · Ebrahim Delpassand, M.D. (1) · Emily Bergsland (1) · Emily K. Bergsland, MD (1) · Guillaume Cadiot (1) · Henry Pitot (1) · Jeffrey F. Geschwind, MD (1) · Jennifer Eads (1)
PMID 21831734, PMID 22480131, PMID 22722717, PMID 25318437, PMID 25488966, PMID 25900182, PMID 25956795, PMID 27020837, PMID 29853660, PMID 31969335, PMID 33362722, PMID 33835977, PMID 33882143, PMID 34380663, PMID 34716198, PMID 36260828, PMID 37702588, PMID 38243705, PMID 38358334, PMID 39067873, PMID 39343510, PMID 39417692, PMID 39583952, PMID 39856213, PMID 39863139, PMID 40402690, PMID 40588371, PMID 41672597, PMID 41892875, PMID 41995270, PMID 42225102, PMID 42499790
P30CA016672 (4), N01CM62205 (3), U10CA180820 (3), N01CM00039 (2), P50CA102701 (2), U01CA076576 (2), U10CA021115 (2), N01CM00032 (1), N01CM00038 (1), N01CM00070 (1), N01CM00071 (1), N01CM00099 (1), N01CM00100 (1), N01CM62201 (1), N01CM62202 (1)